ImmunoPrecise Antibodies Divests Netherlands Subsidiary to AVS Bio
Deal News | Aug 21, 2025 | Orrick
ImmunoPrecise Antibodies Ltd., a biotherapeutics company, has completed the sale of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V., to AVS Bio for $12 million. AVS Bio, backed by Arlington Capital Partners, specializes in bioprocessing and biologics. The deal signifies a strategic pivot for ImmunoPrecise to enhance its AI-driven drug discovery and refine its operational structure. The transaction provides ImmunoPrecise with capital to invest in its proprietary technologies and key strategic programs, aligning with its focus on AI-based SaaS platforms. Orrick advised ImmunoPrecise on this transaction.
Sectors
- Biotherapeutics
- Bioprocessing
Geography
- Netherlands – The article discusses the divestment of IPA's Netherlands-based subsidiary to AVS Bio.
- USA – ImmunoPrecise Antibodies Ltd. is a company listed in the Nasdaq, a stock exchange in the USA.
Industry
- Biotherapeutics – ImmunoPrecise Antibodies operates within the biotherapeutics industry, focusing on developing next-generation biologics and drug discovery solutions.
- Bioprocessing – AVS Bio is involved in the bioprocessing industry, providing inputs and services critical for the production of biologics.
Financials
- $12 million USD – Total enterprise value of the Netherlands-based subsidiary divested by ImmunoPrecise Antibodies to AVS Bio.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ImmunoPrecise Antibodies Ltd. | Selling Company | Company | A biotherapeutics company focused on biologics discovery and development. |
| AVS Bio | Bidding Company | Company | A global provider of critical inputs and services for bioprocessing and biologics industries, and a portfolio company of Arlington Capital Partners. |
| Orrick | Legal Advisor | Company | Law firm that represented ImmunoPrecise Antibodies Ltd. in this transaction. |
| Arlington Capital Partners | Private Equity Firm | Company | A private equity firm backing AVS Bio. |
| Dr. Jennifer Bath | CEO | Person | President and CEO of ImmunoPrecise Antibodies Ltd. |